130 related articles for article (PubMed ID: 10367173)
1. Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group.
Wadler S; Schwartz EL; Anderson P; Runowicz CD; Chuang L; Del Priore G; Hochster H; Goldberg G; Fields A; Loewen G; Haynes H
Cancer J Sci Am; 1999; 5(3):165-70. PubMed ID: 10367173
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial and pharmacokinetic study of 9-cis-retinoic acid (ALRT1057) in pediatric patients with refractory cancer: a joint Pediatric Oncology Branch, National Cancer Institute, and Children's Cancer Group study.
Adamson PC; Widemann BC; Reaman GH; Seibel NL; Murphy RF; Gillespie AF; Balis FM
Clin Cancer Res; 2001 Oct; 7(10):3034-9. PubMed ID: 11595692
[TBL] [Abstract][Full Text] [Related]
3. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial.
Weiss GR; Liu PY; Alberts DS; Peng YM; Fisher E; Xu MJ; Scudder SA; Baker LH; Moore DF; Lippman SM
Gynecol Oncol; 1998 Dec; 71(3):386-90. PubMed ID: 9887236
[TBL] [Abstract][Full Text] [Related]
4. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
Wadler S; Schwartz EL; Haynes H; Rameau R; Quish A; Mandeli J; Gallagher R; Hallam S; Fields A; Goldberg G; McGill F; Jennings S; Wallach RC; Runowicz CD
Cancer; 1997 Apr; 79(8):1574-80. PubMed ID: 9118041
[TBL] [Abstract][Full Text] [Related]
5. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid.
Miller VA; Rigas JR; Benedetti FM; Verret AL; Tong WP; Kris MG; Gill GM; Loewen GR; Truglia JA; Ulm EH; Warrell RP
Clin Cancer Res; 1996 Mar; 2(3):471-5. PubMed ID: 9816192
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
Park SH; Gray WC; Hernandez I; Jacobs M; Ord RA; Sutharalingam M; Smith RG; Van Echo DA; Wu S; Conley BA
Clin Cancer Res; 2000 Mar; 6(3):847-54. PubMed ID: 10741706
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.
Rizvi NA; Marshall JL; Ness E; Yoe J; Gill GM; Truglia JA; Loewen GR; Jaunakais D; Ulm EH; Hawkins MJ
Clin Cancer Res; 1998 Jun; 4(6):1437-42. PubMed ID: 9626460
[TBL] [Abstract][Full Text] [Related]
8. Related case report: in vivo suppression of thyrotropin by 9-cis retinoic acid.
Dabon-Almirante CL; Damle S; Wadler S; Hupart K
Cancer J Sci Am; 1999; 5(3):171-3. PubMed ID: 10367174
[TBL] [Abstract][Full Text] [Related]
9. 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
Mernitz H; Smith DE; Zhu AX; Wang XD
Cancer Lett; 2006 Nov; 244(1):101-8. PubMed ID: 16413115
[TBL] [Abstract][Full Text] [Related]
10. Biological effects and metabolism of 9-cis-retinoic acid and its metabolite 9,13-di-cis-retinoic acid in HaCaT keratinocytes in vitro: comparison with all-trans-retinoic acid.
Chen WC; Sass JO; Seltmann H; Nau H; Orfanos CE; Zouboulis CC
Arch Dermatol Res; 2000 Dec; 292(12):612-20. PubMed ID: 11214822
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
12. Retinoids, cisplatin and interferon-alpha in recurrent or metastatic cervical squamous cell carcinoma: clinical results of 2 phase II trials.
Braud AC; Gonzague L; Bertucci F; Genre D; Camerlo J; Gravis G; Goncalves A; Moutardier V; Viret F; Maraninchi D; Viens P
Eur Cytokine Netw; 2002; 13(1):115-20. PubMed ID: 11956030
[TBL] [Abstract][Full Text] [Related]
13. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of 9-cis retinoic acid in adults with solid tumors.
Kurie JM; Lee JS; Griffin T; Lippman SM; Drum P; Thomas MP; Weber C; Bader M; Massimini G; Hong WK
Clin Cancer Res; 1996 Feb; 2(2):287-93. PubMed ID: 9816171
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetic studies of all-trans-retinoic acid in pediatric patients with cancer.
Adamson PC
Leukemia; 1994; 8 Suppl 3():S22-5. PubMed ID: 7808020
[TBL] [Abstract][Full Text] [Related]
16. Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study.
Hofmann WK; Kell WJ; Fenaux P; Castaigne S; Ganser A; Chomienne C; Burnett R; Kowal C; Hoelzer D; Burnett AK
Leukemia; 2000 Sep; 14(9):1583-8. PubMed ID: 10995004
[TBL] [Abstract][Full Text] [Related]
17. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study.
Miller WH; Reyno LM; Loewen GR; Huan S; Winquist E; Moore M; Cato A; Jaunakais D; Truglia JA; Matthews S; Dancey J; Eisenhauer E
Ann Oncol; 2000 Nov; 11(11):1387-9. PubMed ID: 11142476
[TBL] [Abstract][Full Text] [Related]
18. Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.
Sonawane P; Cho HE; Tagde A; Verlekar D; Yu AL; Reynolds CP; Kang MH
Br J Pharmacol; 2014 Dec; 171(23):5330-44. PubMed ID: 25039756
[TBL] [Abstract][Full Text] [Related]
19. Antitumoral activity of 13-demethyl or 13-substituted analogues of all-trans retinoic acid and 9-cis retinoic acid in the human myeloid leukemia cell line HL-60.
Mizuguchi Y; Wada A; Nakagawa K; Ito M; Okano T
Biol Pharm Bull; 2006 Sep; 29(9):1803-9. PubMed ID: 16946489
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study.
Takekuma M; Hirashima Y; Ito K; Tsubamoto H; Tabata T; Arakawa A; Itani Y; Furukawa N; Murakoshi H; Takeuchi S
Gynecol Oncol; 2012 Sep; 126(3):341-5. PubMed ID: 22609108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
